Procaine HCl acts by reversibly blocking voltage-gated sodium channels, increasing the threshold for neuronal depolarization and slowing propagation of action potentials.2,4

Binding occurs at the intracellular side of the sodium channel, stabilizing the inactivated state and limiting sodium influx.3,4

This process is:

• Frequency-dependent
• Concentration-dependent
• Influenced by drug ionization and local tissue pH

These mechanistic descriptions reflect pharmacologic principles and should not be interpreted as clinical performance guarantees or dosing guidance.

Absorption

Systemic absorption varies with dose, vascularity, and injection site. More vascular tissues demonstrate higher systemic uptake.2

Distribution

Like other ester anesthetics, Procaine exhibits rapid systemic distribution after absorption. Low plasma protein binding contributes to its short duration of systemic exposure.3

Metabolism

Procaine is rapidly hydrolyzed by plasma pseudocholinesterase into PABA and diethylaminoethanol. Individuals with genetic or acquired pseudocholinesterase deficiency may experience prolonged effects.3,4

Elimination

Metabolites are excreted predominantly in urine.7

General Principles

Anesthesia references describe individualizing Procaine Hydrochloride dosing according to the intended clinical application, patient characteristics, injection site, and anticipated systemic absorption. These sources generally emphasize limiting exposure to the amount necessary for the intended anesthetic objective because systemic toxicity is related to circulating drug concentrations.2–4

Because systemic absorption varies according to tissue vascularity, injection technique, and total administered dose, anesthesia references emphasize monitoring for manifestations of central nervous system or cardiovascular toxicity.2–4,7

Administration Considerations

Prior to administration, the solution should be visually inspected for particulate matter and discoloration. Only clear, colorless solutions free of visible particulates should be used.1

General administration precautions described in anesthesia references include:

• Appropriate aseptic technique
• Aspiration, when clinically appropriate, to minimize inadvertent intravascular administration
• Slow administration with monitoring of patient response
• Observation for hypersensitivity reactions and manifestations of local anesthetic systemic toxicity2–4,7

Reported Concentrations and Administration Approaches

Historically, FDA-approved Procaine Hydrochloride injection labeling described administration using 0.25%, 0.5%, 1%, and 2% solutions, with dosing individualized according to the anesthetic procedure, tissue vascularity, injection site, depth of anesthesia required, and the patient’s overall clinical condition.14 Standard anesthesiology references similarly emphasize using the lowest effective amount necessary to achieve the intended anesthetic effect.2–4

Published literature describes a wide range of Procaine dosing regimens depending on the intended clinical application. Historically, Procaine has been administered for:

• Local infiltration anesthesia
• Peripheral nerve blocks
• Diagnostic nerve blocks
• Neural therapy and other investigational injection techniques

The concentrations, injection volumes, and treatment frequency reported in the literature vary considerably and are specific to the individual study protocol or clinical application. These published regimens should not be interpreted as standardized dosing recommendations or evidence of established therapeutic benefit.9–13

Table 1. Reported Concentrations and Administration Approaches. The concentrations and administration approaches summarized below reflect selected published reports and study-specific protocols. They do not represent instructions for preparing, diluting, or administering any particular Procaine Hydrochloride Injection product.

* Historical FDA-approved labeling also described a usual maximum total treatment dose of 1,000 mg; this value reflected the labeled product at the time and is presented for historical context only.

Product-Specific Information

This educational review is not intended to provide prescribing recommendations. Clinical use of Procaine Hydrochloride Injection remains the responsibility of the licensed prescriber and should be based on the authorized prescription or order, the product’s dispensed labeling, applicable institutional policies, and independent professional judgment.

Chemical Stability and Hydrolysis

Procaine Hydrochloride contains an ester functional group that is chemically susceptible to hydrolysis, consistent with the broader class of ester-type local anesthetics.2,3 Hydrolysis results in the formation of para-aminobenzoic acid (PABA) and diethylaminoethanol (DEAE).2,3

Hydrolysis Pathway (Class-Based Behavior)

The ester linkage may undergo hydrolytic degradation influenced by factors known to affect ester stability, including pH, temperature, aqueous environment, and the duration of time in solution.2,3 Alkaline pH conditions are associated with increased ester cleavage, while comparatively acidic environments are more favorable for stability.2,3 These characteristics reflect general ester chemistry principles and may not represent Procaine-specific validated kinetic data.

Light and Visual Appearance Considerations

Published Procaine-specific data regarding light sensitivity are limited. Nevertheless, minimizing unnecessary light exposure is a commonly applied precaution in pharmaceutical handling of ester-containing solutions. Solutions are generally expected to appear clear and colorless; visible discoloration or particulate matter warrants investigation or disposal in accordance with applicable USP and institutional quality procedures.1

Limitations of Stability Principles

These principles describe expected behavior of ester-containing molecules and are not a substitute for formulation-specific stability studies, beyond-use dating, or container-closure validation.

Procaine Hydrochloride has long been used as a short-acting ester local anesthetic. Beyond its established anesthetic role, Procaine has appeared in exploratory and complementary medicine literature, particularly in neural therapy, integrative multimodal injection-based practices, and anti-aging hypotheses. The following subsections summarize investigational areas in which Procaine has been evaluated. These descriptions reflect published inquiry only and do not indicate therapeutic endorsement or regulatory approval.

7.1 Neural Therapy (Local Procaine Injections)

Neural therapy involves injecting dilute Procaine into scars, dermatomes, trigger points, or autonomic regions with the goal of modulating nociceptive or autonomic dysfunction. Several clinical investigations have evaluated this approach.

An observational pain-center cohort (n=280) reported improvement in chronic pain symptoms following neural-therapy injections using local anesthetics, including Procaine.10 Because the study lacked a control group, results cannot determine causality.

A randomized controlled trial evaluating 1% Procaine injections for supraspinatus tendinopathy demonstrated short-term reductions in pain and improved function from baseline.11

Evidence reviews have concluded that although neural therapy is practiced internationally, the available clinical evidence is heterogeneous and underpowered, resulting in insufficient high-quality evidence to determine efficacy.12 Overall, evidence suggests possible short-term symptomatic benefit in select musculoskeletal conditions, but findings remain preliminary and inconsistent.

7.2 Regenerative and Prolotherapy-Associated Injection Procedures

Procaine is occasionally used as an anesthetic component within multimodal injection-based pain treatments in integrative medicine. Reviews of injection-based therapies describe short-acting local anesthetics, including Procaine, as adjunct agents used for procedural analgesia, modulation of nociceptive input, or facilitation of needling techniques.9

In regenerative procedures such as prolotherapy, local anesthetics may be incorporated for patient comfort or procedural support; however, existing literature does not identify Procaine as a primary therapeutic component of prolotherapy. Its involvement in these modalities is considered adjunctive and procedural rather than regenerative, consistent with general anesthetic use rather than Procaine-specific therapeutic effects.9

7.3 Anti-Aging and “Geroprotector” Hypotheses

Procaine has historically been associated with anti-aging claims, partly due to formulations such as “Gerovital H₃.” Modern scientific assessments have reevaluated these claims using contemporary standards.

A 2021 critical review characterized Procaine as a “controversial geroprotector candidate,” citing inconsistent and nonreproducible findings across earlier studies, significant methodological limitations in historical literature, and a lack of evidence supporting systemic anti-aging or longevity effects.13

The investigational and historical uses described in this section reflect published literature only. They do not constitute medical advice, do not imply proven clinical benefit, and are not recognized indications.

Expected Class-Related Adverse Effects

These reactions are described in anesthesiology literature and represent expected pharmacologic responses associated with sodium-channel blockade.2–3,6 Reported effects include local injection-site discomfort or burning, mild erythema or swelling, tingling or altered sensation, and temporary localized numbness. These effects are typically self-limited and related to route of administration and injection technique.

Hypersensitivity

Metabolism of Procaine produces para-aminobenzoic acid (PABA), and ester anesthetics are therefore associated with a higher likelihood of hypersensitivity reactions.2,3 Reported reactions include rash, urticaria, pruritus, bronchospasm, and rare severe allergic reactions. This represents a known class effect among ester anesthetics.

Dose-Related Systemic Toxicity

Systemic toxicity is dose-dependent, correlates with plasma concentrations, and commonly involves the central nervous system and cardiovascular system.2–4

Central nervous system effects may include tinnitus, dizziness, tremors, circumoral numbness, and seizures.

Cardiovascular system effects may include hypotension, bradycardia, conduction abnormalities, and rare cardiovascular collapse. These effects are class-related and described for all local anesthetics.

Injection- or Infusion-Related Reactions

Reported reactions associated with local infiltration or vascular administration include local tissue irritation, hematoma formation, and phlebitis or venous irritation during intravenous infusion.1,3 These reactions are not unique to Procaine.

Drug Interactions

Para-aminobenzoic acid (PABA) may antagonize sulfonamide-class antibiotics, representing a recognized biochemical interaction.3,6

Special Populations – Pseudocholinesterase Deficiency

Individuals with congenital or acquired pseudocholinesterase deficiencies may experience prolonged anesthetic duration due to impaired ester metabolism.2–4

Procaine, similar to other ester-type anesthetics, is subject to hydrolytic degradation in aqueous environments, and this process may be influenced by pH, temperature, and duration in solution. Stability is generally greater in acidic conditions, whereas alkaline environments may accelerate ester cleavage.2,3

Although Procaine-specific light- or thermal-degradation studies are limited, minimizing unnecessary exposure to direct light and heat is consistent with general chemical handling practices for ester-containing solutions.

Procaine solutions should remain clear and colorless; any discoloration or visible particulate matter warrants investigation or disposal in accordance with USP standards and facility quality procedures.1

These considerations are scientific in nature and are not preparation, storage, or beyond-use-date instructions. Actual storage conditions, beyond-use dating, and container-closure requirements must be based on manufacturer labeling, applicable regulations, and validated stability programs.

Procaine Hydrochloride (Procaine HCl) is an ester-type local anesthetic with well-described chemical and pharmacologic properties that are associated with characteristically rapid onset, short duration of systemic exposure, and rapid metabolic clearance.2–3,5 Its mechanism of action involves reversible blockade of voltage-gated sodium channels with preferential affinity for the inactivated state, resulting in temporary interruption of neuronal signal conduction and nociceptive transmission.2–4 Although historical literature describes use in various anesthetic, analgesic, and neuromodulatory contexts,2–5 contemporary evidence remains limited, and much of the published work reflects historic practice patterns, exploratory and mechanistic research, or niche applications outside mainstream clinical protocols.5–6,9

From a clinical safety perspective, Procaine shares class-based adverse event risks associated with local anesthetics, including potential hypersensitivity reactions due to para-aminobenzoic acid (PABA) metabolite formation,3,5–6 and rare but serious systemic toxicity when excessive plasma concentrations occur.3,5–7 Use outside standard anesthetic practice settings—such as investigational, cosmetic, alternative-medicine, or non-regulated wellness applications—underscores the importance of validated formulation quality, professional oversight, controlled administration settings, and adherence to applicable regulatory standards and compounding requirements.1,5,7,9

Further well-designed, controlled studies would be valuable to clarify Procaine’s contemporary therapeutic roles, safety parameters, and comparative utility relative to currently utilized anesthetic agents, as well as to evaluate emerging mechanistic hypotheses under rigorously monitored research conditions.5,9

References

1. 1United States Pharmacopeia (USP). Procaine Hydrochloride Monograph. Rockville, MD: United States Pharmacopeial Convention; 2022.
2. 2Covino BG, Vassallo HG. Local Anesthetics: Mechanisms of Action and Clinical Use. New York, NY: Grune & Stratton; 1976.
3. 3Becker DE, Reed KL. Essentials of local anesthetic pharmacology. Anesth Prog. 2006;53(3):98–109.
4. 4Butterworth JF IV, Strichartz GR. Molecular mechanisms of local anesthesia. Anesthesiology. 1990;72(4):711–734.
5. 5Sheikh NK, Dua A. Procaine. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. Updated May 8, 2023.
6. 6Yagiela JA. Local anesthetics: a century of progress. Anesth Prog. 1985;32(2):46–56.
7. 7El-Boghdadly K, Pawa A, Chin KJ. Local anesthetic systemic toxicity: current perspectives. Local Reg Anesth. 2018;11:35–44.
8. 8Becker DE, Reed KL. Local anesthetics: review of pharmacological considerations. Anesth Prog. 2012;59(2):90–102.
9. 9Vinyes D, Muñoz-Sellart M, Fischer L. Therapeutic use of low-dose local anesthetics in pain, inflammation, and other clinical conditions: a systematic scoping review. J Clin Med. 2023;12(23):7221.
10. 10Egli S, Pfister M, Ludin SM, et al. Long-term results of therapeutic local anesthesia (neural therapy) in 280 referred refractory chronic pain patients. BMC Complement Altern Med. 2015;15:200.
11. 11Bashan I, Ozturk GY. Effect of neural therapy on shoulder dysfunction and pain in supraspinatus tendinopathy. Pak J Med Sci. 2022;38(3 Pt I):565–569.
12. 12Weinschenk S. Neural therapy: a review of the therapeutic use of local anesthetics. Acupunct Relat Ther. 2012;1(1):5–9.
13. 13Gradinaru D, Ungurianu A, Margina D, Moreno-Villanueva M, Bürkle A. Procaine—the controversial geroprotector candidate: new insights regarding its molecular and cellular effects. Oxid Med Cell Longev. 2021;2021:3617042.
14. 14Hospira, Inc. NOVOCAIN® (procaine hydrochloride injection, USP) prescribing information. Lake Forest, IL: Hospira, Inc.; Revised April 2007.

Copyright © 2026 McGuff Outsourcing Solutions. All rights reserved.
No part of this document may be reproduced, distributed, or transmitted in any form or by any means, including photocopying, recording, or electronic transmission, without the prior written permission of McGuff Outsourcing Solutions.